Because different types of technology – such as pharmaceuticals, devices or procedures – may require different kinds of assessment, it was decided that different Core Model applications should be developed for their assessment. This document describes the model application for the rapid relative effectiveness assessment (REA) of pharmaceuticals, entitled the ‘HTA Core Model® for Rapid Relative Effectiveness Asssessment of Pharmaceuticals’ abbreviated as ‘Model for Rapid REA of Pharmaceuticals’.
9 guidelines were developed to help the assessors of evidence interpret and process the data that are presented to them as part of a REA. Below you can find links to the 9 guidelines:
1. Clinical endpoints
2. Composite endpoints
3. Surrogate endpoints
5. Health-related quality of life
6. Criteria for the choice of the most appropriate comparator(s)
7. Direct and indict comparison
8. Internal validity
9. Applicability of evidence in the context of a relative effectiveness assessment
This document is part of the JA1 Final Technical Report as Deliverable “D3-3 WP5_5a_Model_for_Rapid_REA_of_pharmaceuticals_final_version_reduced”
NOTE: For the full Technical Report, please follow this link.
Model for Rapid REA of pharmaceuticals_final_20130311_reduced